Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBMC apheresis collection study for potential CTL019 therapy candidates
NL-OMON43204Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in hematopoietic malignancies, sponsored by Novartis. Primary endpoint: Collection of PBMCs for potential CTL019 research use. Started Jul 2016; status: active, not recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON43204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43204.